SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced record second-quarter revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year. The company's SSi Mantra surgical robotic system continues to drive growth, with installations rising 30.4% to 30 systems during the quarter.
For the first half of 2026, revenue reached $25.0 million, up 65.6% from $15.1 million in the first half of 2025. Gross profit increased 77.5% to $12.4 million, reflecting strong demand for the platform. However, gross margin declined to 50.9% from 59.1% in the year-earlier quarter, partly due to investments in scaling operations.
The company's installed base now stands at 224 SSi Mantra systems across 12 countries, with 12,272 cumulative surgeries performed. This expansion underscores the platform's growing adoption in diverse healthcare markets. SS Innovations has also made notable progress in telesurgery, which is extending the clinical profile of the SSi Mantra and opening new possibilities for remote surgical care.
Looking ahead, regulatory milestones could serve as significant catalysts. The company is targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these approvals would likely expand market access and drive further adoption of the SSi Mantra in major developed regions.
The financial results were reported in a press release issued by SS Innovations, which also highlighted the company's focus on system installations as the primary commercial growth driver. The release notes that gross profit for the first half improved to $12.4 million, up from $7.0 million in the prior-year period, reflecting operational leverage.
Investors and industry observers are closely watching SS Innovations as it competes in the surgical robotics space, which is increasingly crowded with established players and new entrants. The company's rapid revenue growth and expanding installed base suggest strong market acceptance, but the upcoming regulatory decisions will be crucial for long-term success.
While the company did not provide specific guidance for the remainder of 2026, the momentum from the first half suggests continued growth. However, as with all forward-looking statements, these projections are subject to risks and uncertainties that could affect actual results.
